Search research articles
Contact Us
Filters
Showing results (111-120 of 682) with videos related to
Page
of 69
Sort By:
Cancer Treatment Reports
|
November 1, 1986
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma
B M Cantwell, M Earnshaw, A L Harris
Journal of the Royal Society of Medicine
|
July 1, 1994
Assessment of the impact of cancer on work, recreation, home management and sleep using a general health status measure
M Malone, A L Harris, D K Luscombe
Hormone Research
|
January 1, 1989
Endocrinology of Zoladex in postmenopausal women
M Dowsett, B M Cantwell, A L Harris
European Journal of Cancer & Clinical Oncology
|
May 1, 1989
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma
J Carmichael, B M Cantwell, A L Harris
EXS
|
January 1, 1997
Angiogenesis as a biologic and prognostic indicator in human breast carcinoma
K Engels, S B Fox, A L Harris
British Journal of Cancer
|
June 6, 2000
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients
K J O'Byrne, N Dobbs, A L Harris
Breast Cancer Research and Treatment
|
March 5, 1999
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?
D F Hayes, B Trock, A L Harris
Cancer Research
|
October 15, 1988
Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors
K Moses, A L Harris, B W Durkacz
Cancer Research
|
May 1, 1990
Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines
M Chatterjee, C N Robson, A L Harris
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer
B M Cantwell, A L Harris, J M Bozzino
Page
of 69
Search research articles
Search
Showing results (111-120 of 682) with videos related to
Sort By:
Page
of 69
Cancer Treatment Reports
|
November 1, 1986
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma
B M Cantwell, M Earnshaw, A L Harris
Journal of the Royal Society of Medicine
|
July 1, 1994
Assessment of the impact of cancer on work, recreation, home management and sleep using a general health status measure
M Malone, A L Harris, D K Luscombe
Hormone Research
|
January 1, 1989
Endocrinology of Zoladex in postmenopausal women
M Dowsett, B M Cantwell, A L Harris
European Journal of Cancer & Clinical Oncology
|
May 1, 1989
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma
J Carmichael, B M Cantwell, A L Harris
EXS
|
January 1, 1997
Angiogenesis as a biologic and prognostic indicator in human breast carcinoma
K Engels, S B Fox, A L Harris
British Journal of Cancer
|
June 6, 2000
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients
K J O'Byrne, N Dobbs, A L Harris
Breast Cancer Research and Treatment
|
March 5, 1999
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?
D F Hayes, B Trock, A L Harris
Cancer Research
|
October 15, 1988
Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors
K Moses, A L Harris, B W Durkacz
Cancer Research
|
May 1, 1990
Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines
M Chatterjee, C N Robson, A L Harris
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer
B M Cantwell, A L Harris, J M Bozzino
Page
of 69